Compare AMPY & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | ARMP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 199.7M |
| IPO Year | 2011 | 1996 |
| Metric | AMPY | ARMP |
|---|---|---|
| Price | $4.90 | $5.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 917.4K | 94.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.65 | $2.79 |
| 52 Week High | $6.79 | $14.98 |
| Indicator | AMPY | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 53.24 |
| Support Level | $4.49 | $5.12 |
| Resistance Level | $5.07 | $5.63 |
| Average True Range (ATR) | 0.16 | 0.48 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 68.09 | 77.22 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.